These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 11788129)

  • 1. Treating lipid abnormalities in patients with type 2 diabetes mellitus.
    Steiner G
    Am J Cardiol; 2001 Dec; 88(12A):37N-40N. PubMed ID: 11788129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing high-density lipoprotein cholesterol: an update on fenofibrate.
    Després JP
    Am J Cardiol; 2001 Dec; 88(12A):30N-36N. PubMed ID: 11788128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of change in low-density lipoprotein size during lipid-lowering treatment in type 2 diabetes.
    Wägner AM; Ordóñez-Llanos J; Jorba O; Pérez A
    Metabolism; 2004 Nov; 53(11):1516. PubMed ID: 15558848
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
    Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
    Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study.
    Lancet; 2001 Mar; 357(9260):905-10. PubMed ID: 11289345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic dyslipidemia.
    Kreisberg RA
    Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group.
    Steiner G
    Diabetologia; 1996 Dec; 39(12):1655-61. PubMed ID: 9081851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Overviews of fibrate].
    Tada N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():609-17. PubMed ID: 11347141
    [No Abstract]   [Full Text] [Related]  

  • 10. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
    Keating GM; Ormrod D
    Drugs; 2002; 62(13):1909-44. PubMed ID: 12215067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case for lipid-lowering?
    Durrington P
    Diabet Med; 2000 Sep; 17 Suppl 2():4-5. PubMed ID: 11048824
    [No Abstract]   [Full Text] [Related]  

  • 13. The effects of statin and fibrate on lowering small dense LDL- cholesterol in hyperlipidemic patients with type 2 diabetes.
    Tokuno A; Hirano T; Hayashi T; Mori Y; Yamamoto T; Nagashima M; Shiraishi Y; Ito Y; Adachi M
    J Atheroscler Thromb; 2007 Jun; 14(3):128-32. PubMed ID: 17587764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline characteristics of the study population in the Diabetes Atherosclerosis Intervention Study (DAIS). World Health Organization Collaborating Centre for the Study of Atherosclerosis in Diabetes.
    Steiner G; Stewart D; Hosking JD
    Am J Cardiol; 1999 Nov; 84(9):1004-10. PubMed ID: 10569654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus.
    Gutierrez MJ; Rosenberg NL; Macdougall DE; Hanselman JC; Margulies JR; Strange P; Milad MA; McBride SJ; Newton RS
    Arterioscler Thromb Vasc Biol; 2014 Mar; 34(3):676-83. PubMed ID: 24385236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials.
    Sacks FM
    Am J Cardiol; 2001 Dec; 88(12A):14N-18N. PubMed ID: 11788125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS).
    Vakkilainen J; Steiner G; Ansquer JC; Aubin F; Rattier S; Foucher C; Hamsten A; Taskinen MR;
    Circulation; 2003 Apr; 107(13):1733-7. PubMed ID: 12665498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.
    Diabetes Atorvastin Lipid Intervention (DALI) Study Group
    Diabetes Care; 2001 Aug; 24(8):1335-41. PubMed ID: 11473066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of hypercholesterolaemia in the patient with diabetes.
    Packard C; Olsson AG
    Int J Clin Pract Suppl; 2002 Jul; (130):27-32. PubMed ID: 12296606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).
    Ansquer JC; Foucher C; Rattier S; Taskinen MR; Steiner G;
    Am J Kidney Dis; 2005 Mar; 45(3):485-93. PubMed ID: 15754270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.